STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] Ainos, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Ainos Inc. amended its Schedule 13D to report ownership and recent transactions involving the issuer's common stock. After a June 30, 2025 one-for-five reverse stock split, Ainos KY directly holds 491,263 shares, representing 9.13% of the expanded share count basis. The filing discloses additional voting relationships: 933,958 shares under a January 26, 2024 voting agreement with the Tsai Group, 100,500 shares under a March 7, 2024 voting agreement, 635,652 shares tied to ASE Test via a May 3, 2024 agreement (including convertible notes and warrants), 1,037,206 shares under an August 15, 2024 agreement with TCNT, and 55,275 shares under a March 10, 2025 agreement.

The filing states the direct holdings of 491,263 shares were acquired for investment purposes, while TCNT sold 62,794 shares between June 25, 2025 and October 6, 2025 for general operating purposes. No other material contracts beyond the disclosed voting agreements are reported.

Positive

  • Direct stake of 491,263 shares provides clear disclosed economic interest
  • Voting agreements cover large blocks (totaling over 2.8M shares) which can coordinate votes

Negative

  • Direct economic ownership is limited to 9.13% despite broader voting arrangements
  • ASE Test's position includes convertible securities and warrants that may dilute or change control if exercised

Insights

Voting agreements concentrate influence while direct economic ownership is modest.

The reporting party, Ainos KY, holds 491,263 shares directly (9.13% basis) and controls additional voting blocks through multiple voting agreements totaling over 2.8M shares combined, which amplifies its practical voting influence beyond its direct economic stake.

This structure depends on the continued enforceability and terms of the voting agreements and on no material dilution beyond the shares already disclosed. Watch near-term filings for any amendments to these agreements or further sales between now and Q4 2025 that could change voting control or economic exposure.

Recent sales by TCNT modestly reduce affiliated economic exposure but leave voting control mechanisms intact.

TCNT sold 62,794 shares from June 25, 2025 to October 6, 2025 for operating needs; the Schedule clarifies those shares remain subject to the TCNT Voting Agreement for voting purposes where applicable.

Investors should monitor subsequent Schedule 13 filings for changes in percent ownership, disclosures about convertible note conversions or warrant exercises tied to ASE Test, and any new statements revising the issuer's outstanding share count or voting arrangements over the next few quarters.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The number of securities in Row 7 includes, after giving effect to the one-for-five reverse stock split of the Issuer's common stock effected on June 30, 2025 (the "June 2025 Reverse Split"), (i) 491,263 shares of common stock, $0.01 par value, of Ainos, Inc., a Texas corporation (the "Issuer"), owned directly by Ainos Inc., a Cayman Islands company ("Ainos KY"), (ii) 933,958 shares pursuant to a Voting Agreement dated January 26, 2024 (the "2024 Voting Agreement"), by and among the Reporting Person, and Chun-Hsien Tsai, Ting Chuan Lee, Chun-Jung Tsai, and Chung-Yi Tsai (the "Tsai Group"); (iii) 100,500 shares of common stock pursuant to a Voting Agreement dated March 7, 2024 (the "2024 Voting Agreement II") with Chih-Heng Lu; (iv) 635,652 shares pursuant to a Voting Agreement dated May 3, 2024 between Ainos KY and ASE Test, Inc. ("ASE Test" and the "ASE Voting Agreement") (with the 635,652 ASE Test shares consisting of the following (a) 11,777 shares owned by ASE Test, (b) 99,875 shares issuable to ASE Test upon conversion of outstanding convertible notes of the Issuer (c) 424,000 shares issuable to ASE Test upon conversion of a convertible note of the Issuer issuable within 60 days), and (d) 100,000 shares issuable to ASE Test upon exercise of warrants to purchase 100,000 shares of the Issuer with ASE Test, (v) 1,037,206 shares pursuant to a Voting Agreement dated August 15, 2024 between Ainos KY and Taiwan Carbon Nano Technology Corporation ("TCNT Voting Agreement"), and (vi) 55,275 shares pursuant to a Voting Agreement dated March 10, 2025 between Ainos KY and Hsin-Liang Lee (the "2025 Voting Agreement"). The numbers in Rows 9, 11 and 13 represents beneficial ownership of 491,263 shares of common stock of the Issuer, consisting of 491,263 shares owned directly by Ainos KY and excludes (i) 933,958 shares pursuant to the 2024 Voting Agreement; (ii) 100,500 shares of common stock pursuant to the 2024 Voting Agreement II; (iii) 635,652 shares pursuant to the ASE Voting Agreement, (iv) 1,037,206 shares pursuant to a Voting Agreement dated August 15, 2024 between Ainos KY and Taiwan Carbon Nano Technology Corporation, and (v) 55,275 shares pursuant to the 2025 Voting Agreement. The percentage in Row 13 is based on the sum of, after giving effect to the June 2025 Reverse Split, (i) 4,759,021 shares of Common Stock outstanding as of September 5, 2025 as set forth in the prospectus supplement of the Issuer filed with the SEC on September 5, 2025, 2025 and (ii) 623,875 total shares issuable to ASE Test upon conversion of outstanding convertible note and exercisable warrant of the Issuer. This Amendment No. 12 to Schedule 13D ("Amendment No. 11") amends and supplements the Schedule 13D dated April 28, 2021 (the "Original Statement"), as amended and restated by Amendment No. 1 dated December 13, 2023, as amended by Amendment No. 2 dated March 8, 2022, Amendment No. 3 dated September 2, 2022, Amendment No. 4 dated August 15, 2023, Amendment No. 5 dated January 29, 2024, Amendment No. 6 dated March 11, 2024, Amendment No. 7 dated May 6, 2024, Amendment No.8 dated August 20, 2024, Amendment No.9 dated November 26, 2024, Amendment No.10 dated March 12, 2025, and Amendment No. 11 dated April 9, 2025 (the Original Statement, as so amended shall be known as the "Statement"), with respect to the Common Stock of the Issuer. Unless otherwise indicated, all capitalized terms used herein shall have the same meaning as set forth in the Statement. Except as set forth below, there are no changes to the information set forth in the Statement. Items 2, 3, 4, 5 and 6 of the Statement are hereby amended as follows:


SCHEDULE 13D


Ainos Inc.
Signature:/s/ Chun-Hsien Tsai
Name/Title:Chun-Hsien Tsai/Director and CEO
Date:10/09/2025

FAQ

What does Ainos KY own in Ainos, Inc. (AIMD)?

Ainos KY directly owns 491,263 shares, reported as 9.13% on a post-reverse-split basis.

How many shares are subject to voting agreements linked to the reporting person?

Voting agreements disclosed total 933,958 (Tsai Group), 100,500, 635,652 (ASE Test), 1,037,206 (TCNT-related), and 55,275 shares.

Did any sales occur recently by affiliated parties?

Yes. TCNT sold 62,794 shares between June 25, 2025 and October 6, 2025 for general operating purposes.

Were there corporate actions that affected share counts?

The issuer effected a one-for-five reverse stock split on June 30, 2025, which adjusted reported share counts.

Are there other agreements that could affect voting or dilution?

Yes. The ASE Voting Agreement includes shares issuable from convertible notes and warrants totaling portions of the 635,652 shares disclosed.
Ainos Inc

NASDAQ:AIMD

AIMD Rankings

AIMD Latest News

AIMD Latest SEC Filings

AIMD Stock Data

9.24M
1.94M
56.73%
0.13%
2.59%
Medical Devices
Pharmaceutical Preparations
Link
United States
SAN DIEGO